TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2865156

Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor blocker (propranolol)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Combined alpha- and beta-adrenoceptor blocker (labetalol)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Untreated hypertensives
Number of subjects: 3
Study: 31012970

Group type: EXPERIMENTAL
Intervention: Garmin Vivofit 2 activity monitor with behavioral feedback and goal‐setting session and 5 telephone‐delivered health coaching sessions
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study: 29493846

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: EDITS and IIEF EF domain scores
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: EDITS and EHS instrument scores
Number of subjects: 279
Study: 27630373

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg or 1.0 mg administered at tumor localization and every 2 months for 24 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 40
Study: 24077371

Group type: EXPERIMENTAL
Intervention: GRD (dive on the ground and complete a rolling sequence)
Number of subjects: 10

Group type: COMPARATOR
Intervention: STD (complete the shuttles while staying on their feet)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GRD with nose clip
Number of subjects: 10

Group type: COMPARATOR
Intervention: STD with nose clip
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GRD
Number of subjects: 10

Group type: COMPARATOR
Intervention: STD
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 10
Study: 22302233

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Social support control group
Number of subjects: 20
Study: 19068079

Group type: EXPERIMENTAL
Intervention: 10 mg delta(9)-THC
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 mg delta(9)-THC
Number of subjects: 18

Group type: COMPARATOR
Intervention: delta(9)-THC with SR141716A (CB(1) receptor antagonist)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17909384

Group type: EXPERIMENTAL
Intervention: PBE‐CPI studies
Number of subjects: 0
Study: 16637731

Group type: EXPERIMENTAL
Intervention: Damon 2 bracket
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional twin bracket
Number of subjects: 60
Study: 12835430

Group type: EXPERIMENTAL
Intervention: Assure (fluoride‐releasing light‐cured compomer)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Unite & MIP (chemically‐cured composite resin with moisture‐resistant primer)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Assure
Number of subjects: 25
Study: 11004025

Group type: EXPERIMENTAL
Intervention: Tracheal extubation in the operating room (OR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tracheal extubation in the intensive care unit (ICU)
Number of subjects: 100
Study: 8792777

Group type: EXPERIMENTAL
Intervention: HMO experimental group (free fee-for-service chiropractic care)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HMO control group (95% cost sharing for chiropractic services)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fee-for-service care (with cost sharing)
Number of subjects: 0
Study: 1281732

Group type: EXPERIMENTAL
Intervention: Laser recanalization
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endoscopic intubation
Number of subjects: 40
Study: 6693788

Group type: EXPERIMENTAL
Intervention: Aminoglycosides (gentamicin, tobramycin, amikacin)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (non-toxic patients)
Number of subjects: 135
Study: 29395236

Group type: COMPARATOR
Intervention: 20 mm Hg (low pressure)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 25 mm Hg (high pressure)
Number of subjects: 31
Study: 27175657

Group type: EXPERIMENTAL
Intervention: EALM therapy (esomeprazole 40 mg bid and amoxicillin 1 g bid for 5 days, followed by esomeprazole 40 mg bid, levofloxacin 500 mg qd, and metronidazole 500 mg tid, for 5 days)
Number of subjects: 164

Group type: COMPARATOR
Intervention: 10-day EAL therapy (levofloxacin 500 mg qd, amoxicillin 1 g bid, and esomeprazole 40 mg bid)
Number of subjects: 164
Study: 24703972

Group type: EXPERIMENTAL
Intervention: 100% oxygen dives
Number of subjects: 10

Group type: COMPARATOR
Intervention: Air dives
Number of subjects: 10
Study: 20840223

Group type: EXPERIMENTAL
Intervention: Supervised implementation of the oral health care guideline
Number of subjects: 360

Group type: COMPARATOR
Intervention: Non-supervised implementation of the oral health care guideline
Number of subjects: 360
Study: 20110140

Group type: EXPERIMENTAL
Intervention: Hydrolysed formula feeding
Number of subjects: 833

Group type: COMPARATOR
Intervention: Cow's milk formula
Number of subjects: 833
Study: 18596969

Group type: EXPERIMENTAL
Intervention: HPC containing 0.3% FGF-2
Number of subjects: 74

Group type: COMPARATOR
Intervention: HPC with no FGF-2 (Group P)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: HPC containing 0.1% FGF-2 (Group M)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: HPC containing 0.03% FGF-2 (Group L)
Number of subjects: 74
Study: 16858953

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole (aspirin 300 mg/d + dipyridamole 75 mg thrice a day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Aspirin alone (300 mg/d)
Number of subjects: 38
Study: 12242455

Group type: EXPERIMENTAL
Intervention: Group care (systemic education)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Individual consultations and education (control)
Number of subjects: 56
Study: 10638394

Group type: EXPERIMENTAL
Intervention: 5-mg oral doses of amlodipine (reference formulation)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5-mg oral doses of amlodipine (test formulation)
Number of subjects: 16
Study: 7490595

Group type: EXPERIMENTAL
Intervention: Prepayment of $5 along with the mailed survey
Number of subjects: 400

Group type: COMPARATOR
Intervention: Promise of $5 on return of a completed survey
Number of subjects: 400
Study: 1788636

Group type: EXPERIMENTAL
Intervention: Ultra-high streptokinase therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional streptokinase dosage
Number of subjects: 0
Study: 7270985

Group type: EXPERIMENTAL
Intervention: Weekly injections of ragweed antigen
Number of subjects: 9

Group type: COMPARATOR
Intervention: Monthly injections of ragweed antigen
Number of subjects: 9
Study: 30672255

Group type: EXPERIMENTAL
Intervention: Herb-separated moxibustion combined with sulfasalazine enteric-coated tablets
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional moxibustion combined with sulfasalazine enteric-coated tablets
Number of subjects: 64
Study: 27776560

Group type: EXPERIMENTAL
Intervention: Memantine for 1 year
Number of subjects: 31
Study: 25488040

Group type: EXPERIMENTAL
Intervention: Reperfusion within 90 minutes of hospital contact
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Median door-to-balloon (D2B) time
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Time from hospital contact to informed consent by region
Number of subjects: 337
Study: 24112528

Group type: EXPERIMENTAL
Intervention: 5% N2O added to 60-minute CO2 pneumoperitoneum
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10% N2O added to CO2 pneumoperitoneum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood (1 mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma
Number of subjects: 0
Study: 21044117

Group type: EXPERIMENTAL
Intervention: Aldosterone levels before adrenalectomy (235.0 ± 51.1 pg/ml)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Na(+) ‐K(+) ‐ATPase activity before adrenalectomy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Correlation of Na(+) ‐K(+) ‐ATPase activity with plasma aldosterone levels
Number of subjects: 6
Study: 18362933

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 0
Study: 16547688

Group type: EXPERIMENTAL
Intervention: Calcitriol treatment (1 microg/day for 7 days)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Phylloquinone repletion (450 microg per day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Phylloquinone depletion (4-week)
Number of subjects: 21
Study: 12968960

Group type: EXPERIMENTAL
Intervention: Fibrin glue (4 ml) applied to wound surfaces and under the flap
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 54
Study: 11068889

Group type: EXPERIMENTAL
Intervention: Child-alone cognitive-behavioral treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Family cognitive-behavioral treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Parent-completed measures and clinician ratings of global functioning
Number of subjects: 36
Study: 9160652

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg)
Number of subjects: 0
Study: 1358037

Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 3882619

Group type: EXPERIMENTAL
Intervention: Nonionic contrast agent (iohexol)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Ionic contrast agent (sodium methylglucamine diatrizoate)
Number of subjects: 273
Study: 30994776

Group type: EXPERIMENTAL
Intervention: In‐office bleaching with two applications of 35% hydrogen peroxide (HP) (20 minutes), followed by at‐home bleaching with 10% carbamide peroxide (CP) (2 hours/day for 16 days)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Same protocol as G1, plus desensitizing toothpaste
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: In‐office bleaching with 35% HP and one application of placebo gel (20 minutes), followed by at‐home bleaching with 10% CP (2 hours/day for 16 days)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Same protocol as G3, plus desensitizing toothpaste
Number of subjects: 80
Study: 29764190

Group type: EXPERIMENTAL
Intervention: Delafloxacin
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Vancomycin with or without aztreonam
Number of subjects: 1400
Study: 26990892

Group type: EXPERIMENTAL
Intervention: Single high-dose melphalan followed by autologous transplantation (HDM/ASCT)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Tandem high-dose melphalan followed by autologous transplantation (HDM/ASCT)
Number of subjects: 358
Study: 24506834

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 66
Study: 23519436

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg kg‐1
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg kg‐1
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 225
Study: 21048963

Group type: EXPERIMENTAL
Intervention: Cellulose Sulfate 6% (CS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quality control guidelines
Number of subjects: 0
Study: 18387931

Group type: EXPERIMENTAL
Intervention: Rimonabant (20 mg daily)
Number of subjects: 839

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 839
Study: 16794097

Group type: EXPERIMENTAL
Intervention: ACB assay in group 2 (moderately injured patients with ISS >15)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: ACB assay in group 1 (mildly injured patients with ISS <15)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (30 healthy volunteers)
Number of subjects: 92
Study: 12745983

Group type: EXPERIMENTAL
Intervention: Cycling with a schoolbag (6 kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cycling without a schoolbag
Number of subjects: 20
Study: 11679528

Group type: EXPERIMENTAL
Intervention: GnRH analogue (leuprolide acetate depot, 3.75 mg, monthly i.m. injections for 3 months)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Expectant management (no treatment)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: GnRH analogue
Number of subjects: 89

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 89
Study: 9706454

Group type: EXPERIMENTAL
Intervention: GnRH agonist therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8169405

Group type: EXPERIMENTAL
Intervention: cold‐recombinant, trivalent influenza vaccine
Number of subjects: 22
Study: 3127050

Group type: EXPERIMENTAL
Intervention: Deprenyl 5 mg b.i.d.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 31248064

Group type: EXPERIMENTAL
Intervention: C‐LCCT
Number of subjects: 40

Group type: COMPARATOR
Intervention: TT
Number of subjects: 40
Study: 28270737

Group type: EXPERIMENTAL
Intervention: Total Face Mask (TFM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oronasal Mask (ONM)
Number of subjects: 48
Study: 25809565

Group type: EXPERIMENTAL
Intervention: Home-based telehealth
Number of subjects: 52

Group type: COMPARATOR
Intervention: In-person prolonged exposure
Number of subjects: 52
Study: 23517885

Group type: EXPERIMENTAL
Intervention: Pramipexole (0.375 mg/day titrated to 2.25 mg/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Combination of pramipexole and escitalopram
Number of subjects: 39
Study: 21803570

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CAIRO study)
Number of subjects: 1526

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus targeted therapy (CAIRO2 study)
Number of subjects: 1526
Study: 19538647

Group type: EXPERIMENTAL
Intervention: Online communication with 'Informed Supporters', people who had been managing their bipolar disorder effectively for 2 years or more, as part of an online psycho-education programme.
Number of subjects: 26
Study: 16679991

Group type: EXPERIMENTAL
Intervention: Steadiness training with light loads (30% of 1-RM, 10 reps per set, 3 sets per session, 3 sessions per week for 16 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (9 subjects)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Steadiness training
Number of subjects: 21
Study: 14648127

Group type: COMPARATOR
Intervention: Control (CON) trial
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sauna (SAU) trial
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Face cooling during exercise (CON(FAN) and SAU(FAN))
Number of subjects: 10
Study: 11371411

Group type: EXPERIMENTAL
Intervention: Group SE (structured educational program emphasizing self-capacity to manage asthma exacerbations)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Group SE
Number of subjects: 126

Group type: COMPARATOR
Intervention: Group C (control; usual treatment)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Group LE (limited education; teaching of the inhaler technique plus self-action plan)
Number of subjects: 126
Study: 9228363

Group type: EXPERIMENTAL
Intervention: Treadmill exercise protocol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bicycle exercise protocol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 21
Study: 7965250

Group type: EXPERIMENTAL
Intervention: Maternity support program participants
Number of subjects: 220

Group type: COMPARATOR
Intervention: Nonparticipants of the maternity support program
Number of subjects: 220
Study: 29016474

Group type: EXPERIMENTAL
Intervention: Kettlebell (KB) exercise
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nonexercise control trial
Number of subjects: 17
Study: 31219668

Group type: EXPERIMENTAL
Intervention: Nurse-led clinic with person-centred care and frequent visits
Number of subjects: 70

Group type: COMPARATOR
Intervention: Regular care (control group)
Number of subjects: 70
Study: 29425904

Group type: EXPERIMENTAL
Intervention: MP-AzeFlu
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: LORA/INFP
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 28001244

Group type: EXPERIMENTAL
Intervention: Bonded molars (using composite resin)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Banded molars (cemented with glass ionomer)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Banded lower molars
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bonded lower molars
Number of subjects: 32
Study: 25214548

Group type: EXPERIMENTAL
Intervention: Isolated RLN injury group (n = 26)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Concurrent SLN/RLN injury group (n = 8)
Number of subjects: 34
Study: 22759326

Group type: EXPERIMENTAL
Intervention: Empirical concomitant therapy (PPI, amoxicillin 1 g, clarithromycin 500 mg, metronidazole 500 mg; all drugs b.i.d.)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Concomitant therapy for clarithromycin-susceptible H. pylori
Number of subjects: 298

Group type: COMPARATOR
Intervention: Concomitant therapy for clarithromycin-resistant strains
Number of subjects: 298
Study: 20922563

Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/d)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 18555939

Group type: EXPERIMENTAL
Intervention: Aminaftone 75 mg TID for 12 weeks
Number of subjects: 24
Study: 16052297

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both DES and BMS
Number of subjects: 75
Study: 12449290

Group type: EXPERIMENTAL
Intervention: Commercial antioxidant supplement (dried fruit and vegetable extracts, fortified with antioxidants, gummy-type candy), taken in 2 doses per day for 21 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo, taken in 2 doses per day for 21 days
Number of subjects: 39
Study: 10366112

Group type: EXPERIMENTAL
Intervention: High-dose D-penicillamine (750-1,000 mg/day)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Low-dose D-penicillamine (125 mg every other day)
Number of subjects: 134
Study: 8808186

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (CTX)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58
Study: 2042095

Group type: EXPERIMENTAL
Intervention: Pylorus and antroseromuscular flap-preserving subtotal gastrectomy (PAFPG)
Number of subjects: 125
Study: 7025719

Group type: EXPERIMENTAL
Intervention: High dose cisplatin (120 mg/m2) with vindesine
Number of subjects: 85

Group type: COMPARATOR
Intervention: Low dose cisplatin (60 mg/m2) with vindesine
Number of subjects: 85
Study: 31688572

Group type: EXPERIMENTAL
Intervention: E2 vaginal inserts (4, 10, or 25 μg)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: E2 vaginal inserts
Number of subjects: 695
Study: 28903965

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) plus low-dose corticosteroids
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low-dose corticosteroids (monotherapy)
Number of subjects: 41
Study: 27236596

Group type: EXPERIMENTAL
Intervention: Education and self-care group (ESG)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Education group (EG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study: 24613333

Group type: EXPERIMENTAL
Intervention: HeartMate II LVAD (PA group)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Historical comparison group (TR group)
Number of subjects: 247
Study: 22041126

Group type: EXPERIMENTAL
Intervention: High intensity aerobic training (HI: 80% maximum heart rate, n=10)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Low intensity aerobic training (LI: 55% of maximum heart rate, n=10)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (n=11)
Number of subjects: 31
Study: 20195641

Group type: EXPERIMENTAL
Intervention: Minimally invasive video‐assisted thyroidectomy (MIVAT), n = 23
Number of subjects: 49

Group type: COMPARATOR
Intervention: Traditional thyroidectomy (OPEN), n = 26
Number of subjects: 49
Study: 17670916

Group type: EXPERIMENTAL
Intervention: Glucose solution (75 g in 300 ml water)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Water (300 ml)
Number of subjects: 17
Study: 15591328

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg kg(‐1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 22
Study: 11893258

Group type: EXPERIMENTAL
Intervention: Cellophane patch
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gentamicin ointment seal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gentamicin plug (Control)
Number of subjects: 30
Study: 9568918

Group type: EXPERIMENTAL
Intervention: Phase-locked echo-tracking method
Number of subjects: 95
Study: 7607777

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention including a 10-minute educational session and a nine-step self-help manual.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual clinic care
Number of subjects: 0
Study: 2220138

Group type: EXPERIMENTAL
Intervention: New trocar-cannula combination (10 French)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard Cystofix system (10 French)
Number of subjects: 149
Study: 371561

Group type: EXPERIMENTAL
Intervention: Diflunisal (250 mg b.i.d.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naproxen (250 mg b.i.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30897686

Group type: EXPERIMENTAL
Intervention: Bacteriophage consumption for 28 days
Number of subjects: 0
Study: 28696047

Group type: COMPARATOR
Intervention: Food Safety Guidelines (FSGs)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Neutropenic Diet + Food Safety Guidelines (ND + FSGs)
Number of subjects: 150
Study: 26482247

Group type: EXPERIMENTAL
Intervention: Dialysate sodium reduced from 138mmol/l to 136mmol/l
Number of subjects: 64

Group type: COMPARATOR
Intervention: Dialysate sodium remained at 138mmol/l
Number of subjects: 64
Study: 24935363

Group type: EXPERIMENTAL
Intervention: Etoposide-cisplatin alternating with vinorelbine-cisplatin (EP-NP)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Etoposide-cisplatin (EP)
Number of subjects: 82